Frederic Vigant

Title: **Frederic Vigant: Innovator in Genetically Modified Lymphocytes**

Introduction

Frederic Vigant, a prominent inventor based in Villers Sous Saint Leu, France, has made significant contributions to the field of genetic engineering, particularly in the modification of lymphocytes. With a focus on enhancing the efficiency and effectiveness of genetic modification techniques, he stands out as a crucial player in advanced therapeutic development.

Latest Patents

Frederic Vigant holds a patent titled "Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL." This innovative patent outlines methods and compositions designed to genetically modify lymphocytes, specifically T cells and NK cells, in shorter durations and within whole blood or its components. Notably, the patent introduces a lymphodepletion filter assembly, which can be utilized before or after the formation of a reaction mixture. This advancement enables the efficient genetic modification of lymphocytes by contacting them with recombinant retroviral particles in a closed system.

Career Highlights

Vigant's career is distinguished by his work at Exuma Biotech Corporation, a company recognized for its groundbreaking research in biotechnology. His expertise in genetic engineering and lymphocyte modification underscores the importance of his contributions to the sector. As a dedicated inventor, he has positioned himself as a pivotal figure in the advancement of therapeutic techniques, particularly in treating various diseases through innovative biotechnological methods.

Collaborations

Throughout his career, Frederic Vigant has collaborated with esteemed colleagues, including Gregory Ian Frost and James Joseph Onuffer, Jr. These collaborations have enhanced his research endeavors and facilitated the development of cutting-edge biotechnological solutions, reinforcing the significance of teamwork in scientific innovation.

Conclusion

Frederic Vigant exemplifies the spirit of innovation in the biotechnology field, particularly in the realm of genetically modified lymphocytes. His patent developments and collective efforts with fellow researchers showcase a commitment to advancing therapeutic approaches aimed at improving health outcomes. With ongoing contributions to the field, his work may pave the way for future breakthroughs in medical science.